Related Experiment Videos
Advances in the surgical management of sarcomas in children
1Department of Surgery, University of Texas Medical School at Houston, Pediatric Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 6431 Fannin, MSB 4.020, 77030, USA. Richard.Andrassy@uth.tmc.edu
Insights
Advances in multimodal therapy have significantly improved survival rates for children with soft tissue sarcomas, reducing the need for extensive surgeries and associated morbidity. Early surgical involvement in treatment planning is crucial for managing these rare pediatric cancers.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Cancer Research
Background:
- Soft tissue sarcomas in children have seen improved survival over the last 30 years.
- Multimodal treatment approaches have reduced the need for radical surgeries, enhancing outcomes.
- Early surgical involvement is key in managing pediatric soft tissue sarcomas, including rhabdomyosarcomas (RMS) and nonrhabdomyosarcomas soft-tissue sarcomas (NRSTS).
Discussion:
- Multimodal therapy, including chemotherapy and radiation, alongside surgical intervention, has become standard for pediatric soft tissue sarcomas.
- Cooperative clinical trials, such as the Intergroup Rhabdomyosarcoma Study, have demonstrated improved survival and less invasive surgical techniques.
- The rarity of these tumors necessitates collaborative research efforts to refine treatment protocols.
Key Insights:
- Improved survival and decreased morbidity in pediatric soft tissue sarcomas are attributed to multimodal treatment strategies.
- Systematic management involving early surgical planning, diagnosis, and treatment phases optimizes patient care.
- Cooperative trials are essential for advancing knowledge on surgical extent and adjuvant therapies for rare pediatric sarcomas.
Outlook:
- Continued participation in cooperative trials is vital for addressing remaining questions in pediatric soft tissue sarcoma management.
- Further research will focus on optimizing surgical techniques and adjuvant therapies to improve long-term outcomes.
- The development of targeted therapies and personalized treatment plans holds promise for future advancements.
Abstract:
The management of children with soft tissue sarcomas has changed and survival has improved markedly during the past three decades. This is, in large part, due to the multi-modal approach to pediatric malignancies; decreasing the need for radical surgical procedures, while improving survival and decreasing morbidity. The management of patients with rhabdomyosarcomas (RMS) and nonrhabdomyosarcomas soft-tissue sarcomas (NRSTS) as well as neurofibromatosis and related tumors is best accomplished in an organized and systematic fashion with the surgeon involved early in the planning, diagnostic, and treatment phases. Cooperative trials for rhabdomyosarcoma, as part of the Intergroup Rhabdomyosarcoma Study, have led to improved survival with less radical surgery. Ongoing trials of the Soft Tissue Sarcoma Group of the Children's Oncology Group are under way. Since these tumors are rare, cooperative trials are essential to answering the remaining questions regarding extent of surgery and adjuvant therapy.